3 sources·Health

FDA Approves Zepbound as First Drug for Obstructive Sleep Apnea

Eli Lilly's Zepbound is now FDA-approved for treating obesity-related obstructive sleep apnea, potentially expanding insurance coverage for millions of patients.

The distribution of story sources: left-leaning (blue), center (light gray), and right-leaning (red).
Reliable
The underlying sources consistently report facts with minimal bias, demonstrating high-quality journalism and accuracy.
Balanced
The underlying sources are either a balanced mix of left and right or primarily centrist.

No highlights available for this story.

Updated: Dec 20th, 2024, 7:29 PM ET

Summary

A summary of the key points of this story verified across multiple sources.

The FDA has approved Eli Lilly's weight-loss drug Zepbound for treating moderate to severe obstructive sleep apnea in adults with obesity. This marks the first drug option for this condition, affecting around 30 million Americans. Studies indicate that Zepbound can significantly reduce apnea events and improve overall symptoms, while also contributing to weight loss. Despite its potential, insurance coverage remains a concern due to its high cost, as many plans currently do not cover obesity-related treatments. The approval signifies a major advancement in the treatment of obstructive sleep apnea linked to obesity.

Perspectives

Compare opinions on this story from liberal (Left), conservative (Right) or center-leaning news organizations.

No center-leaning sources available for this story.